Immatics US
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Immatics US sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Immatics US: 7 sponsored US clinical trials, 3 recruiting.
Immatics US sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Cancer, with 2 trials.
Upper-quartile sponsor footprint
Immatics US sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124
TCR-engineered T Cells in Solid Tumors: IMA202-101
NCT03441100
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
NCT03760952
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
NCT03247309
ACTolog in Patients With Solid Cancers
NCT02876510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Immatics US pipeline
3 recruiting of 7 indexed (43% open); 4 completed (57%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Recurrent Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Immatics US: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Immatics US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Immatics US page
7 registered trials is a research-attention snapshot, not an endorsement of Immatics US or any single study.
- 3 of Immatics US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Cancer is the condition Immatics US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Immatics US pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.